29 August 2024 - BeiGene's anti-PD-1 immuno-oncology drug Tevimbra (tislelizumab) and Handok's FGFR inhibitor Pemazyre (pemigatinib) have passed the Cancer Disease Review Committee (CDRC), the first gateway to receiving insurance benefits, after a second attempt.

On Wednesday, HIRA released the results of the deliberations on reimbursement standards for cancer drugs, including updates to reflect clinical reality at the sixth CDRC meeting this year.

Read Korea Biomedical Review article